XML 81 R66.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Apr. 30, 2021
Apr. 30, 2020
Income tax benefits $ (895)
Deferred tax assets, valuation allowance 45,091 42,431
Increase (decrease) in valuation allowance 2,700 (700)
Net operating loss carry forwards $ 173,000  
Operating loss carryforwards, expiration description Begin to expire in fiscal 2022  
Net operating loss subject to no expiration $ 36,600  
Operating loss carryforwards, deductibility limitation The deductibility of such federal net operating losses may be limited to 80% of our taxable income in future years.  
Deferred tax assets, tax credit carryforwards, research and development $ 3,303 3,076
Proceed from sale of loss carryforwards and tax credits 12,000 10,000
Interest or penalties accrued on uncertain tax positions  
Spain [Member]    
Income tax description The Company is currently undergoing an income tax audit in Spain for the period from 2011 to 2014  
Uncertain tax positions
Interest or penalties accrued on uncertain tax positions  
Research and Development Expense [Member]    
Proceeds from sale of credit 1,000 $ 900
Research and Development Expense [Member] | New Jersey [Member]    
Income tax description   New Jersey-based technology or biotechnology companies with fewer than 225 US employees may be eligible to sell net operating losses and research and development tax credits to unaffiliated corporations, up to a maximum lifetime benefit of $20 million per business.
Research and Development Expense [Member] | New Jersey [Member] | Maximum [Member]    
Proceeds from sale of credit   $ 20,000
State and Local Jurisdiction [Member]    
Income tax benefits 1,000 $ 900
Net operating loss carry forwards $ 21,300  
Operating loss carryforwards, expiration description Begin to expire in 2039, which also may be limited to utilization limitations.  
Foreign [Member]    
Net operating loss carry forwards $ 18,900